Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entereg for opioid-induced bowel dysfunction in non-cancer pain
NCT00256932Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of alvimopan in opioid-induced bowel dysfunction (OIBD), sponsored by Merck & Co.. Started Aug 2005; status: completed.
02
Drugs
alvimopan
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT00256932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256932.